Pacific Biosciences of California (PACB) Shares are Up 0.24%

Pacific Biosciences of California (PACB) : During the past 4 weeks, traders have been relatively bearish on Pacific Biosciences of California (PACB), hence the stock is down -3.22% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.29% relative to the S&P 500. The stock has risen by 0.24% in the past week indicating that the buyers are active at lower levels, but the stock is down -5.18% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 1.53% and the 50-Day Moving Average is 1.47%.The 200 Day SMA reached 9.74% Pacific Biosciences of California, Inc. has dropped 2.55% during the last 3-month period . Year-to-Date the stock performance stands at -35.87%.


Pacific Biosciences of California (PACB) : 4 Wall Street analysts covering Pacific Biosciences of California (PACB) believe that the average level the stock could reach for the short term is $12.75. The maximum price target given is $18 and the minimum target for short term is around $11, hence the standard deviation is calculated at $3.5.

For the current week, the company shares have a recommendation consensus of Buy. Pacific Biosciences of California (NASDAQ:PACB): stock was range-bound between the intraday low of $8.25 and the intraday high of $8.54 after having opened at $8.46 on Fridays session. The stock finally closed in the red at $8.46, a loss of -0.36%. The stock remained in the red for the whole trading day. The total traded volume was 1,641,747 shares. The stock failed to cross $8.54 in Fridays trading. The stocks closing price on Thursday was $8.42.

Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.